NCT04560582

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.

Detailed description

This is an observational cohort study collecting data and blood specimens at designated time points. The primary outcome will be comparing the cPRA in patients that have a rise in cf-DNA to those that do not have a rise in cf-DNA. Seondary outcomes include comparison of the combined incidence of need for transfusion, need for methylprednisolone and allograft nephrectomy, ESA dose, allograft tenderness, and gross hematuria.

Conditions

• Kidney Transplant; Complications
• Kidney Transplant Rejection
• Kidney Transplant Failure

Interventions

Type	Name	Description
PROCEDURE	Blood Draw	Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.

Timeline

• Start date: 2022-09-22
• Primary completion: 2023-09-01
• Completion: 2023-10-01
• First posted: 2020-09-23
• Last updated: 2023-11-29

Locations

1 site across 1 country: United States